ANIX

Anixa Biosciences Stock Price

3.18
-0.12 (-3.64%)
Upgrade to Real-Time
Regular Market
3.18
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Anixa Biosciences Inc ANIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.12 -3.64% 3.18 3.13 3.31 3.30 3.30 11:09:43
Bid Price Ask Price Spread Spread % News
3.17 3.19 0.02 0.63% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
815 168,822 $ 3.24 $ 546,310 461,673 1.33 - 5.45
Last Trade Time Type Quantity Stock Price Currency
11:09:43 100 $ 3.18 USD

Anixa Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 76.21M 23.52M 20.71M $ 250.00k $ - -0.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 77.45k 20.60%

more financials information »

Anixa Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ANIX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.024.302.853.22804,0870.165.3%
1 Month2.114.302.042.91483,9741.0750.71%
3 Months2.154.301.702.36445,9561.0347.91%
6 Months2.894.301.332.40240,7560.2910.03%
1 Year4.145.451.332.74153,915-0.96-23.19%
3 Years4.486.861.333.27121,579-1.30-29.02%
5 Years4.486.861.333.27121,579-1.30-29.02%

Anixa Biosciences Description

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumors which is based on the body's immune response to the presence of a malignancy. The company also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer a patient's own immune cells to fight cancer.


Your Recent History
NASDAQ
ANIX
Anixa Bios..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.